



Pre-Diagnostic Plasma 25-Hydroxyvitamin D Levels and Risk of Non-Melanoma Skin Cancer in Women

Citation

Liang, Geyu, Hongmei Nan, Abrar A. Qureshi, and Jiali Han. 2012. Pre-diagnostic plasma 25-hydroxyvitamin D levels and risk of non-melanoma skin cancer in women. PLoS ONE 7(4): e35211.

Published version

<https://doi.org/10.1371/journal.pone.0035211>

Link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:10121032>

Terms of use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at

<https://harvardwiki.atlassian.net/wiki/external/NGY5NDE4ZjgzNTc5NDQzMGIzZWZhMGFIOWI2M2EwYTg>

Accessibility

<https://accessibility.huit.harvard.edu/digital-accessibility-policy>

Share Your Story

The Harvard community has made this article openly available.

Please share how this access benefits you. [Submit a story](#)

Pre-Diagnostic Plasma 25-Hydroxyvitamin D Levels and Risk of Non-Melanoma Skin Cancer in Women

Geyu Liang¹, Hongmei Nan^{2,5}, Abrar A. Qureshi^{2,3}, Jiali Han^{2,3,4*}

1 Key Laboratory of Environmental Medicine Engineering of Ministry of Education, School of Public Health, Southeast University, Nanjing, China, **2** Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, **3** Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, **4** Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America, **5** Division of Cancer Epidemiology, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, United States of America

Abstract

Background: Recent reports have shown that vitamin D status was inversely associated with the risk of various cancers. However, few studies examined the association between vitamin D levels and risk of skin cancer.

Methods: We prospectively evaluated the association between baseline plasma 25(OH)D levels and the risk of incident squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) among 4,641 women from the Nurses' Health Study (NHS) and the NHS II with 510 incident BCC cases and 75 incident SCC cases. We used multivariate logistic regression models to calculate odds ratios (ORs) and 95% confidence intervals (CIs).

Results: Plasma 25(OH)D levels were positively associated with risk of BCC after adjusting for age at blood draw, season of blood draw, lab batch, hair color, burning tendency, the number of sunburns, and ultra-violet B flux of residence at blood collection. Women in the highest quartile of 25(OH)D had more than 2-fold increased risk of BCC compared with women in the lowest quartile (OR = 2.07, 95% CI = 1.52–2.80, P for trend < 0.0001). We also found a significantly positive association between plasma 25(OH)D levels and SCC risk after adjusting for the same covariates (OR, highest vs. lowest quartile = 3.77, 95% CI = 1.70–8.36, P for trend = 0.0002).

Conclusion: In this prospective study of women, plasma vitamin D levels were positively associated with non-melanoma skin cancer risk. Considering that most circulating vitamin D is due to sun exposure, the positive association between plasma vitamin D and non-melanoma skin cancer is confounded by sun exposure. Our data suggest that one-time measurement of plasma vitamin D levels may reasonably reflect long-term sun exposure and predict the risk of non-melanoma skin cancer.

Citation: Liang G, Nan H, Qureshi AA, Han J (2012) Pre-Diagnostic Plasma 25-Hydroxyvitamin D Levels and Risk of Non-Melanoma Skin Cancer in Women. PLoS ONE 7(4): e35211. doi:10.1371/journal.pone.0035211

Editor: Yiqing Song, Brigham & Women's Hospital, and Harvard Medical School, United States of America

Received: February 3, 2012; **Accepted:** March 12, 2012; **Published:** April 6, 2012

Copyright: © 2012 Liang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work is supported by NIH grants CA50385, CA67262, CA87969, and CA49449. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: jiali.han@channing.harvard.edu

Introduction

Skin cancer, the most common malignancy, has been increasing rapidly over the past decades in the United States, especially in women [1–3]. Mounting epidemiologic evidence has suggested that vitamin D may be associated with reduced risk of various types of cancers, including colorectal [4], prostate [5], breast [6], pancreatic [7], and lung cancers [8]. However, few studies have examined the association between vitamin D levels and risk of skin cancer, and the data are inconsistent [9–11].

It is more difficult to study the relationship between vitamin D and skin cancer than other internal cancers because vitamin D is predominantly produced in the skin by ultraviolet B (UVB) exposure, which is the well-established risk factor for skin cancer. UVB exposure-synthesized vitamin D in the skin usually contributes 80–90% to total vitamin D in the human body [12]. Only small amount of vitamin D is derived from other sources

including dietary intake. 25-hydroxyvitamin D [25(OH)D] is produced in the liver by a hydroxylation reaction [13]. Circulating plasma 25(OH)D is considered to be the best biomarker of vitamin D status because it reflects the total vitamin D levels [14]. Three epidemiologic investigations have suggested conflicting associations of skin cancer with vitamin D levels [9–11]. In an analysis of the Osteoporotic Fractures in Men Study, inverse association between plasma vitamin D levels and risk of non-melanoma skin cancer in elderly men was found [9]. However, in two other recent analyses of health maintenance organization populations, higher plasma vitamin D levels were significantly associated with increased risk of non-melanoma skin cancer [10,11]. Although experimental studies have shown that vitamin D treatment can inhibit proliferation of melanoma and basal cell carcinomas *in vitro* [15,16], recent evidence in a large cohort of postmenopausal women suggests that daily supplementation of vitamin D did not reduce incidence of skin cancer [17]. However, this study using

low dose vitamin D supplementation (400 IU/day) may not offer informative evidence regarding the potential influence of vitamin D status on skin cancer development [17].

Here we prospectively assess the association between plasma 25(OH)D levels and the risk of non-melanoma skin cancer in a nested case-control study among women from two large ongoing cohort studies: the Nurses' Health Study (NHS) and NHS II.

Methods

Ethics Statement

The institutional review board of Brigham and Women's Hospital approved this study. Participants' completion and return of the self-administered questionnaire was considered to imply informed consent.

NHS Nested Case-control Study

In 1976, 121,700 female registered nurses between 30 and 55 years old were enrolled in the NHS. Women completed an initial questionnaire and have been followed biennially by questionnaire to update information on exposure status and to identify newly diagnosed case subjects of cancer and other medical conditions. Between 1989 and 1990, blood samples were collected from 32,826 participants for analysis. Measurements of plasma 25(OH)D levels were available from a subset of the women who served as controls in several nested case-control studies of chronic diseases conducted previously, including breast cancer, colon polyps, colon cancer and ovarian cancer [18–21]. Eligible cases in this study were Caucasian women with incident skin squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) occurring after blood collection but before 2008. The rest of the subjects were controls. Participants who had previously diagnosed skin cancer before blood collection were excluded from the analysis. The nested case-control study consisted of 387 BCC cases, 67 SCC cases, and 1,641 controls.

NHS II Nested Case-control Study

The NHS II was established in 1989 among 116,609 female registered nurses between the ages of 25 and 42. Participants completed biennial mailed questionnaires to update exposure status and disease diagnoses. Between 1996 and 1999, 29,611

participants provided blood samples. We used all the controls from previous nested case-control studies of chronic disease within the NHS II blood cohort that had been analyzed for vitamin D, including hypertension, breast cancer and ovarian cancer [19,22,23]. The inclusive and exclusive conditions of cases and controls were the same as for the NHS. Eligible cases were Caucasian women with incident skin SCC or BCC occurring after blood collection and the rest of the subjects were controls. The follow-up ended in 2007. Participants who had previously diagnosed skin cancer before blood collection were excluded. The nested case-control study consisted of 123 BCC cases, 8 SCC cases, and 2,415 controls.

Identification of BCC and SCC

We have routinely identified cases of BCC and SCC in both cohorts. Participants reported new diagnoses biennially. With their permission, participants' medical records were obtained and reviewed by physicians to confirm their self-reported diagnosis. Only pathologically confirmed invasive SCC cases were included in this study. Medical records were not obtained for self-reported cases of BCC, but the validity of BCC self-reports was more than 90% in validation studies in our cohorts in early years [24,25]. In this analysis, cases were diagnosed after blood collection and up to 2008 (NHS) and 2007 (NHS II).

Measurement of Plasma 25(OH)D

Plasma 25(OH)D concentrations were measured using radioimmunoassay or chemiluminescence immunoassay, which have been described in detail previously [26,27]. In the NHS, laboratory assays were completed in 14 batches of 4 studies from 1996 to 2004 (3 batches in 1996, 4 batches in 2000, and 7 batches in 2004). In the NHS II, blood samples were assayed in 3 batches of 3 studies (1 batch in 2003 and 2 batches in 2005). Blinded replicate quality-control samples were interspersed throughout the sets for assessing variability. The intra-assay coefficients of variation (CV) were <17.6%.

Statistical Analysis

In the nested case-control study of SCC or BCC, 25(OH)D measurements (continuous in ng/mL) were categorized into quartiles according to the distribution in control population of

Table 1. Characteristics by quartile of plasma vitamin D concentrations in NHS and NHS II.

	NHS				NHS II			
	1st quartile	2nd quartile	3rd quartile	4th quartile	1st quartile	2nd quartile	3rd quartile	4th quartile
25-Hydroxyvitamin D concentrations, ng/mL								
n	484	518	535	558	629	629	639	649
Age at blood draw (y)	57.5(7.1)	57.6(6.7)	57.9(6.9)	58.0(6.8)	44.6(4.2)	44.0(4.2)	43.6(4.4)	43.4(4.4)
Red or blonde hair color (%)	16.7	16.1	15.9	18.7	19.3	20.1	23.6	20.3
Burning tendency (%)	35.6	38.9	38.4	32.2	33.0	25.7	24.1	24.1
Numbers of sunburns (≥5, %)	5.7	6.3	8.8	6.3	8.8	8.8	10.2	10.1
Season of blood draw								
Summer (%)	20.7	30.9	30.1	36.6	10.1	15.5	22.3	28.8
Spring and Fall (%)	45.3	48.3	43.9	44.4	57.4	57.9	57.6	56.5
Winter (%)	34.1	20.9	26.0	19.0	32.5	26.6	20.1	14.8
UVB flux (>113, %)	26.1	28.6	38.4	37.4	41.3	41.8	48.5	50.5

Values are presented as means (Standard deviation) or percentages.
doi:10.1371/journal.pone.0035211.t001

NHS and NHS II study separately. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated to examine the relationship between plasma 25(OH)D levels and SCC or BCC by multivariate logistic regression models. Age at blood draw (in years), season of blood draw [summer (June-August), fall (September-November), winter (December-February), and spring (March-May)], and laboratory batch were included as independent variables in all models. Hair color (1 = red, 2 = blonde, 3 = light brown, 4 = dark brown, 5 = black), burning tendency (1 = practically none, 2 = some redness only, 3 = burn, 4 = painful burn, 5 = painful burn with blisters), the number of sunburns (1 = never, 2 = 1–2, 3 = 3–5, 4 = ≥6), and average annual UV-B flux at residence (≤113 and >113) were also adjusted for in the multivariate models. Pooled analyses of two cohort studies were conducted by merging data sets.

A previous study indicated that seasonal variation may introduce biased results of 25(OH)D levels [28]. Therefore, we conducted stratified analysis to test the interaction of vitamin D and season of blood draw. We modeled season of blood draw as a three-category variable (summer, spring and fall, winter). We tested two multiplicative interaction terms by the likelihood ratio test, comparing the model with the interaction terms with the model containing just the main effects of vitamin D and season of blood draw variables, along with the same covariates. To test interaction of vitamin D and UVB flux, we modeled UVB flux as a dichotomous variable (113 as a cutoff point). We tested one multiplicative interaction term by the likelihood ratio test. Finally, to summarize multiple variables, we constructed a multivariate confounder score [29] to create a pigmentation score for BCC.

Briefly, we applied the logistic regression coefficients from a multivariate model including age, hair color, burning tendency, and the number of sunburns of BCC to each individual's values for the latter three of these variables and summed the values to compute a pigmentation score. We used this score to identify participants with light and dark pigmentation phenotypes based on the median score.

We tested one multiplicative interaction term between vitamin D and pigmentation by the likelihood ratio test. Statistical analyses were conducted using SAS software (version 9, SAS Institute, Cary, NC). All statistical tests were two-sided.

Results

The characteristics of women by quartiles of plasma 25(OH)D concentration in two cohorts are presented in Table 1. Women who provided blood samples in summer tended to have higher 25(OH)D levels than those whose blood was drawn in winter, which is consistent with previously published data [30]. In addition, women with higher 25(OH)D levels were more likely to reside in areas of higher UVB flux.

The associations between plasma vitamin D levels and BCC and SCC were examined separately (Tables 2 and 3). Similar significantly positive findings were obtained between plasma 25(OH)D and risk of BCC in both cohorts in multivariate models (P for trend <0.0001 and =0.01). Women in the highest quartile of 25(OH)D had about 2-fold increased risk of BCC compared with women in the lowest quartile, both in NHS (OR = 2.28, 95% CI = 1.58–3.29) and in NHS II (OR = 1.93, 95% CI = 1.10–3.37). Results were similar when combining the data of NHS and NHS

Table 2. Odds ratios of BCC by quartile of plasma vitamin D concentrations in NHS and NHS II.

	25-Hydroxyvitamin D concentrations, ng/mL				P for trend
	1st quartile	2nd quartile	3rd quartile	4th quartile	
NHS					
Quartile values	≤20.4	20.4–27.0	27.0–34.2	>34.2	
n, case/control	69/406	86/420	108/405	124/410	
OR ^a	1.00(reference)	1.21(0.85–1.72)	1.63(1.16–2.30)	2.25(1.58–3.23)	<.0001
OR ^b	1.00(reference)	1.19(0.83–1.69)	1.59(1.12–2.25)	2.28(1.59–3.29)	<.0001
OR ^c	1.00(reference)	1.18(0.83–1.68)	1.57(1.11–2.23)	2.28(1.58–3.29)	<.0001
NHS II					
Quartile values	≤19.6	19.6–25.5	25.5–31.4	>31.4	
n, case/control	24/604	26/602	34/603	39/606	
OR ^a	1.00(reference)	1.19(0.67–2.10)	1.62(0.93–2.81)	1.93(1.12–3.35)	0.01
OR ^b	1.00(reference)	1.20(0.68–2.13)	1.64(0.94–2.86)	1.94(1.11–3.38)	0.01
OR ^c	1.00(reference)	1.20(0.67–2.13)	1.63(0.93–2.85)	1.93(1.10–3.37)	0.01
Total					
n, case/control	93/1010	112/1022	142/1008	163/1016	
OR ^d	1.00(reference)	1.19(0.88–1.61)	1.59(1.19–2.13)	2.07(1.54–2.79)	<.0001
OR ^e	1.00(reference)	1.17(0.87–1.59)	1.55(1.16–2.08)	2.07(1.53–2.80)	<.0001
OR ^f	1.00(reference)	1.17(0.86–1.58)	1.54(1.15–2.07)	2.07(1.52–2.80)	<.0001

Abbreviation: OR, odds ratio.

^aAdjusted for age at blood draw, season of blood draw, lab batch.

^bAdjusted for age at blood draw, season of blood draw, lab batch, hair color, burning tendency, numbers of sunburns.

^cAdjusted for age at blood draw, season of blood draw, lab batch, hair color, burning tendency, numbers of sunburns, UVB flux.

^dAdjusted for age at blood draw, season of blood draw, lab batch, cohort.

^eAdjusted for age at blood draw, season of blood draw, lab batch, cohort, hair color, burning tendency, numbers of sunburns.

^fAdjusted for age at blood draw, season of blood draw, lab batch, cohort, hair color, burning tendency, numbers of sunburns, UVB flux.

doi:10.1371/journal.pone.0035211.t002

Table 3. Odds ratios of SCC by quartile of plasma vitamin D concentrations in NHS and NHS II.

	25-Hydroxyvitamin D concentrations, ng/mL				P for trend
	1st quartile	2nd quartile	3rd quartile	4th quartile	
NHS					
Quartile values	≤20.4	20.4–27.0	27.0–34.2	>34.2	
n, case/control	9/406	12/420	22/405	24/410	
OR ^a	1.00(reference)	1.43(0.59–3.47)	2.84(1.27–6.37)	3.56(1.56–8.13)	0.0006
OR ^b	1.00(reference)	1.48(0.60–3.60)	2.95(1.30–6.70)	3.79(1.63–8.80)	0.0004
OR ^c	1.00(reference)	1.49(0.61–3.66)	3.04(1.33–6.95)	3.96(1.68–9.34)	0.0004
NHS II					
Quartile values	≤19.6	19.6–25.5	25.5–31.4	>31.4	
n, case/control	1/604	1/602	2/603	4/606	
OR ^a	1.00(reference)	1.03(0.06–16.79)	1.94(0.16–22.76)	3.43(0.34–34.42)	0.20
OR ^b	1.00(reference)	1.33(0.08–22.46)	2.54(0.20–32.28)	4.22(0.39–45.28)	0.17
OR ^c	1.00(reference)	1.48(0.08–27.86)	2.62(0.19–36.30)	4.95(0.41–59.28)	0.15
Total					
n, case/control	10/1010	13/1022	24/1008	28/1016	
OR ^d	1.00(reference)	1.37(0.59–3.18)	2.73(1.27–5.87)	3.62(1.67–7.84)	0.0002
OR ^e	1.00(reference)	1.43(0.61–3.33)	2.87(1.32–6.22)	3.87(1.76–8.49)	0.0001
OR ^f	1.00(reference)	1.40(0.60–3.28)	2.81(1.29–6.12)	3.77(1.70–8.36)	0.0002

^aAdjusted for age at blood draw, season of blood draw, lab batch.

^bAdjusted for age at blood draw, season of blood draw, lab batch, hair color, burning tendency, numbers of sunburns.

^cAdjusted for age at blood draw, season of blood draw, lab batch, hair color, burning tendency, numbers of sunburns, UVB flux.

^dAdjusted for age at blood draw, season of blood draw, lab batch, cohort.

^eAdjusted for age at blood draw, season of blood draw, lab batch, cohort, hair color, burning tendency, numbers of sunburns.

^fAdjusted for age at blood draw, season of blood draw, lab batch, cohort, hair color, burning tendency, numbers of sunburns, UVB flux.

doi:10.1371/journal.pone.0035211.t003

Table 4. Odds ratios of BCC by quartile of plasma vitamin D concentrations in NHS and NHS II (stratified by season of blood draw).

season of blood draw	25-Hydroxyvitamin D concentrations, ng/mL ^d				P for trend
	1st quartile	2nd quartile	3rd quartile	4th quartile	
Summer					
n, case/control	25/138	33/224	44/259	56/333	
OR ^a	1.00(reference)	0.73(0.40–1.34)	0.90(0.50–1.64)	0.95(0.53–1.72)	0.81
OR ^b	1.00(reference)	0.68(0.37–1.27)	0.88(0.48–1.62)	0.93(0.50–1.70)	0.82
OR ^c	1.00(reference)	0.68(0.37–1.27)	0.88(0.48–1.62)	0.93(0.51–1.71)	0.81
Spring and fall					
n, case/control	41/536	61/550	84/517	95/516	
OR ^a	1.00(reference)	1.46(0.93–2.29)	2.26(1.46–3.49)	3.08(1.99–4.78)	<.0001
OR ^b	1.00(reference)	1.45(0.92–2.29)	2.11(1.36–3.29)	2.97(1.90–4.63)	<.0001
OR ^c	1.00(reference)	1.45(0.92–2.29)	2.10(1.35–3.28)	2.97(1.90–4.63)	<.0001
Winter					
n, case/control	37/331	31/243	38/229	39/162	
OR ^a	1.00(reference)	1.38(0.79–2.40)	1.41(0.81–2.45)	2.29(1.27–4.13)	0.01
OR ^b	1.00(reference)	1.35(0.76–2.40)	1.47(0.83–2.60)	2.58(1.39–4.77)	0.005
OR ^c	1.00(reference)	1.33(0.75–2.37)	1.44(0.81–2.57)	2.53(1.36–4.72)	0.006

^aAdjusted for age at blood draw, lab batch, cohort.

^bAdjusted for age at blood draw, lab batch, cohort, hair color, burning tendency, numbers of sunburns.

^cAdjusted for age at blood draw, lab batch, cohort, hair color, burning tendency, numbers of sunburns, UVB flux.

^dP for interaction between season of blood draw and 25-hydroxyvitamin D is 0.09 after adjusted for age at blood draw, lab batch, cohort.

doi:10.1371/journal.pone.0035211.t004

Table 5. Odds ratios of BCC by quartile of plasma vitamin D concentrations in NHS and NHS II (stratified by UVB flux).

UVB flux	25-Hydroxyvitamin D concentrations, ng/mL ^c				P for trend
	1st quartile	2nd quartile	3rd quartile	4th quartile	
≤113					
n, case/control	60/666	88/648	94/564	113/556	
OR ^a	1.00(reference)	1.49(1.02–2.17)	1.82(1.24–2.67)	2.62(1.77–3.89)	<.0001
OR ^b	1.00(reference)	1.49(1.02–2.18)	1.81(1.23–2.67)	2.66(1.78–3.97)	<.0001
>113					
n, case/control	43/343	37/374	72/443	78/458	
OR ^a	1.00(reference)	0.79(0.47–1.31)	1.24(0.79–1.95)	1.45(0.90–2.33)	0.04
OR ^b	1.00(reference)	0.80(0.47–1.34)	1.25(0.78–1.98)	1.52(0.94–2.46)	0.03

^aAdjusted for age at blood draw, season of blood draw, lab batch, cohort.

^bAdjusted for age at blood draw, season of blood draw, lab batch, cohort, hair color, burning tendency, numbers of sunburns.

^cP for interaction between UVB flux and 25-hydroxyvitamin D is 0.07 after adjusted for age at blood draw, season of blood draw, lab batch, cohort.

doi:10.1371/journal.pone.0035211.t005

II (OR = 2.07, 95% CI = 1.52–2.80, P for trend <0.0001) (Table 2).

We noted significantly positive associations between quartiles of 25(OH)D levels and SCC in NHS (OR = 3.96, 95% CI = 1.68–9.34, P for trend = 0.0004). In NHS II, although a similar trend was observed, the result was not statistically significant because only eight cases were identified. Overall, the positive association between 25(OH)D levels and SCC was significant after combining the two cohorts (P for trend = 0.0002). Women in the highest quartile of 25(OH)D had more than a 3-fold increased risk for SCC compared with women in the lowest quartile (OR = 3.77, 95% CI = 1.70–8.36) (Table 3).

We further examined the association between plasma 25(OH)D levels and BCC risk stratified by season of blood draw, UVB flux, and pigmentation (Tables 4, 5, 6). There was a significant positive association between 25(OH)D and risk of BCC among women with blood collection in spring/fall (OR = 2.97, 95% CI = 1.90–4.63) or in winter (OR = 2.53, 95% CI = 1.36–4.72), whereas no association was observed among women with blood collection in summer (OR = 0.93, 95% CI = 0.51–1.71) (P for interaction = 0.09) (Table 4). In the stratified analysis by UVB flux, women who lived in lower UVB flux (≤113) areas tended to have higher

OR (2.66, 95% CI = 1.78–3.97) when comparing the top to bottom quartile of 25(OH)D levels (P for interaction = 0.07) (Table 5). The positive association between 25(OH)D and risk of BCC appeared to be stronger among women with light pigmentation (P for interaction = 0.15) (Table 6).

Discussion

In this study, higher plasma 25(OH)D levels were associated with greater non-melanoma skin cancer risk among women from two large cohorts. In subgroup analysis, higher plasma 25(OH)D tended to increase risk of BCC in women whose blood was collected outside the summer season, who were from areas with less UVB flux (≤113), and among those with light pigmentation. To our knowledge, the current study is one of the largest to provide important evidence on the association of pre-diagnostic plasma 25(OH)D levels with non-melanoma skin cancer.

Vitamin D is predominantly produced in the skin by UVB exposure, which usually contributes 80–90% to total vitamin D in the human body [12]. Our data suggest that one-time measurement of plasma vitamin D levels may reasonably reflect long-term sun exposure. The validity of single 25(OH)D measures was also

Table 6. Odds ratios of BCC by quartile of plasma vitamin D concentrations in NHS and NHS II (stratified by pigmentation).

pigmentation	25-Hydroxyvitamin D concentrations, ng/mL ^c				P for trend
	1st quartile	2nd quartile	3rd quartile	4th quartile	
Light pigmentation					
n, case/control	46/522	53/531	81/488	97/498	
OR ^a	1.00(reference)	1.08(0.69–1.69)	1.84(1.20–2.81)	2.35(1.53–3.61)	<.0001
OR ^b	1.00(reference)	1.08(0.69–1.68)	1.81(1.18–2.78)	2.31(1.50–3.56)	<.0001
Dark pigmentation					
n, case/control	57/488	72/491	85/520	94/518	
OR ^a	1.00(reference)	1.26(0.84–1.91)	1.38(0.92–2.08)	1.84(1.20–2.82)	0.005
OR ^b	1.00(reference)	1.26(0.83–1.91)	1.38(0.91–2.08)	1.85(1.21–2.85)	0.005

^aAdjusted for age at blood draw, season of blood draw, lab batch, cohort.

^bAdjusted for age at blood draw, season of blood draw, lab batch, cohort, UVB flux.

^cP for interaction between UVB flux and 25-hydroxyvitamin D is 0.15 after adjusted for age at blood draw, season of blood draw, lab batch, cohort.

doi:10.1371/journal.pone.0035211.t006

evaluated in NHS. The intraclass correlation coefficients for plasma 25(OH)D measured over 3 years and over 10–11 years were 0.72 and 0.50, respectively [31]. This indicates that a single 25(OH)D measurement is fairly reproducible over years and reasonably reflects long-term vitamin D status. It is well known that sun exposure is the main cause of skin cancers. Therefore, plasma 25(OH)D levels may predict the risk of non-melanoma skin cancer.

Recently, Eide et al. [10] reported a positive relationship between plasma levels of 25(OH)D and non-melanoma skin cancer (adjusted OR, 1.8; 95% CI, 1.1–2.9), including SCC and BCC, in a study of 3223 white health maintenance organization patients who sought advice about the risk of osteoporosis or low bone density. The 25(OH)D levels were similarly positively associated with non-melanoma skin cancer risk at anatomical locations less exposed to UV (adjusted OR, 2.2; 95% CI, 0.7–7.0). In another nested case-control study, Asgari et al. [11] also found an increased risk of BCC with higher vitamin D levels among 220 BCC patients and 220 matched controls from the Kaiser Permanente Northern California Health Maintenance Organization (adjusted OR, 2.09; 95% CI, 0.95–4.58). The results of this study support the findings from Eide et al. and Asgari et al., with similar risk estimated for BCC. However, Tang et al. [9] found an inverse association between higher plasma 25(OH)D levels and risk of non-melanoma skin cancer (OR, 0.6; 95% CI, 0.37–0.98) among 930 white men from the Osteoporotic Fractures in Men Study. It should be noted that all the participants in this study and most of the patients of Eide et al. were women, but the participants in study of Tang et al. were men. Furthermore, the cohorts in our study were followed up for more than 10 years, and the Eide et al. cohort was followed for almost 10 years, but the patients of Tang et al. were followed up for only 5 years. Lastly, our study had the largest sample size. These differences may explain the variations between the results in this study and those of Tang et al.

Stratified analysis on season suggests that 25(OH)D is positively associated with BCC risk among women whose blood was collected outside the summer months. In addition, we observed that the associations between plasma 25(OH)D and BCC risk were stronger among women from areas with less UVB flux. Similar to previous report [32], our data support that plasma 25(OH)D could reasonably reflect long-term vitamin D status more accurately outside the summer season or in areas of less UVB flux. In a case-control study, an inverse association between 25(OH)D and lung cancer was also found only among those whose blood was drawn during the darker months [33].

References

- Miller DL, Weinstock MA (1994) Nonmelanoma skin cancer in the United States: Incidence. *J Am Acad Dermatol* 30: 774–778.
- Christenson LJ, Borrowman TA, Vachon CM, Tollefson MM, Otley CC, et al. (2005) Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. *JAMA* 294: 681–690.
- Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA (2009) Increasing burden of melanoma in the United States. *J Invest Dermatol* 129: 1666–1674.
- Wu K, Feskanich D, Fuchs CS, Willett WC, Hollis BW, et al. (2007) A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. *J Natl Cancer Inst* 99: 1120–1129.
- Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P (2000) Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). *Cancer Causes Control* 11: 847–852.
- Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N (2009) Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. *J Clin Oncol* 27: 3757–3763.
- Skinner HG, Michaud DS, Giovannucci E, Willett WC, Colditz GA, et al. (2006) Vitamin D intake and the risk for pancreatic cancer in two cohort studies. *Cancer Epidemiol Biomarkers Prev* 15: 1688–1695.
- Zhou W, Suk R, Liu G, Park S, Neuberger DS, et al. (2005) Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. *Cancer Epidemiol Biomarkers Prev* 14: 2303–2309.
- Tang JY, Parimi N, Wu A, Boscardin WJ, Shikany JM, et al. (2010) Inverse association between serum 25(OH) vitamin D levels and non-melanoma skin cancer in elderly men. *Cancer Causes Control* 21: 387–391.
- Eide MJ, Johnson DA, Jacobsen GR, Krajenta RJ, Rao DS, et al. (2011) Vitamin D and Nonmelanoma Skin Cancer in a Health Maintenance Organization Cohort. *Arch Dermatol* 147: 1379–1384.
- Asgari MM, Tang J, Warton ME, Chren MM, Quesenberry CP Jr., et al. (2010) Association of prediagnostic serum vitamin D levels with the development of basal cell carcinoma. *J Invest Dermatol* 130: 1438–1443.
- Garcia VC, Martini LA (2010) Vitamin D and cardiovascular disease. *Nutrients* 2: 426–437.
- Hollis MF (2010) Vitamin D: extraskelatal health. *Endocrinol Metab Clin North Am* 39: 381–400.
- Hollis BW (1996) Assessment of vitamin D nutritional and hormonal status: what to measure and how to do it. *Calcif Tissue Int* 58: 4–5.
- Seifert M, Rech M, Meineke V, Tilgen W, Reichrath J (2004) Differential biological effects of 1,25-dihydroxyvitamin D3 on melanoma cell lines in vitro. *J Steroid Biochem Mol Biol* 89–90: 375–379.
- Tang JY, Xiao T, Wu A, Chang KS, Shpall E, et al. (2011) Vitamin D3 inhibits hedgehog signaling and proliferation in murine basal cell carcinomas. *Cancer Prev Res (Phila)* 4: 744–751.

Vitamin D may be of importance in skin cancer development. Although the data from various types of cancer suggest a benefit from high vitamin D levels, they could be a marker of high sun exposure and an increased risk of skin cancer. There is *in vitro* evidence that vitamin D treatment decreases cell growth and metastasis [15,16], but most of the cases studied were melanoma. Evidence *in vitro* for the role of vitamin D in non-melanoma skin cancer is still limited. Mice with inactivated vitamin D receptor had more non-melanoma skin cancer [34]. Vitamin D3 inhibited the proliferation of basal cell carcinomas by inhibiting the hedgehog signaling pathway [16]. The evidence in humans of a positive relationship between vitamin D and non-melanoma skin cancer suggests that UV exposure may have a predominant adverse influence that exceeds any putative benefit from the higher levels of vitamin D.

The strengths of the current study include its prospective design, large well-characterized study population, long follow-up duration, and data on potential confounders. The limitation is that blood samples were not assayed at the same time and in the same laboratory, although we have controlled for batch variation in the multivariate models.

In conclusion, this prospective study found a positive association between plasma 25(OH)D levels and risk of non-melanoma skin cancer. Additionally, for BCC, this association was more apparent among women with blood collection outside the summer season, women from areas with less UVB flux, and light-pigmented women. Considering that most circulating vitamin D is due to sun exposure, the positive association between plasma vitamin D and non-melanoma skin cancer is confounded by sun exposure. Our results suggest that one-time measurement of plasma vitamin D may reasonably reflect long-term sun exposure and predict the risk of non-melanoma skin cancer.

Acknowledgments

We thank the participants in the NHS and NHS II Studies for their dedication and commitment. We also thank the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY.

Author Contributions

Conceived and designed the experiments: JH AAQ HN. Analyzed the data: GL JH. Wrote the paper: GL JH.

17. Tang JY, Fu T, Leblanc E, Manson JE, Feldman D, et al. (2011) Calcium plus vitamin D supplementation and the risk of non-melanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial. *J Clin Oncol* 29: 3078–3084.
18. Feskanich D, Ma J, Fuchs CS, Kirkner GJ, Hankinson SE, et al. (2004) Plasma vitamin D metabolites and risk of colorectal cancer in women. *Cancer Epidemiol Biomarkers Prev* 13: 1502–1508.
19. Tworoger SS, Lee IM, Buring JE, Rosner B, Hollis BW, et al. (2007) Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer. *Cancer Epidemiol Biomarkers Prev* 16: 783–788.
20. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, et al. (2007) Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. *Hypertension* 49: 1063–1069.
21. Green AK, Hankinson SE, Bertone-Johnson ER, Tamimi RM (2010) Mammographic density, plasma vitamin D levels and risk of breast cancer in postmenopausal women. *Int J Cancer* 127: 667–674.
22. Eliassen AH, Spiegelman D, Hollis BW, Horst RL, Willett WC, et al. (2011) Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses' Health Study II. *Breast Cancer Res* 13: R50.
23. Forman JP, Curhan GC, Taylor EN (2008) 25-hydroxyvitamin D levels and risk of incident hypertension among young women. *Hypertension* 52: 828–832.
24. Colditz GA, Martin P, Stampfer MJ, Willett WC, Sampson L, et al. (1986) Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. *Am J Epidemiol* 123: 894–900.
25. Hunter DJ, Colditz GA, Stampfer MJ, Rosner B, Willett WC, et al. (1990) Risk factors for basal cell carcinoma in a prospective cohort of women. *Annals of epidemiology* 1: 13–23.
26. Hollis BW (1997) Quantitation of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D by radioimmunoassay using radioiodinated tracers. *Methods Enzymol* 282: 174–186.
27. Wagner D, Hanwell HE, Vieth R (2009) An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. *Clin Biochem* 42: 1549–1556.
28. Wang Y, Jacobs EJ, McCullough ML, Rodriguez C, Thun MJ, et al. (2009) Comparing methods for accounting for seasonal variability in a biomarker when only a single sample is available: insights from simulations based on serum 25-hydroxyvitamin D. *Am J Epidemiol* 170: 88–94.
29. Miettinen OS (1976) Stratification by a multivariate confounder score. *American journal of epidemiology* 104: 609–620.
30. Baraké R, Weiler H, Payette H, Gray-Donald K (2010) Vitamin D status in healthy free-living elderly men and women living in Quebec, Canada. *J Am Coll Nutr* 29: 25–30.
31. Kotsopoulos J, Tworoger SS, Campos H, Chung FL, Clevenger CV, et al. (2010) Reproducibility of plasma and urine biomarkers among premenopausal and postmenopausal women from the Nurses' Health Studies. *Cancer Epidemiol Biomarkers Prev* 19: 938–946.
32. Karohl C, Su S, Kumari M, Tangpricha V, Veledar E, et al. (2010) Heritability and seasonal variability of vitamin D concentrations in male twins. *Am J Clin Nutr* 92: 1393–1398.
33. Weinstein SJ, Yu K, Horst RL, Parisi D, Virtamo J, et al. (2011) Serum 25-hydroxyvitamin D and risk of lung cancer in male smokers: a nested case-control study. *PLoS One* 6: e20796.
34. Zinser GM, Sundberg JP, Welsh J (2002) Vitamin D(3) receptor ablation sensitizes skin to chemically induced tumorigenesis. *Carcinogenesis* 23: 2103–2109.